XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia

American Journal of Hematology

Volumn 85, Issue 7, 2010, Pages 482-486

  Guillem, Vicent M ^a   Cervantes, Francisco ^b   Martínez, Jesús ^c   Alvarez Larrán, Alberto ^d   Collado, María ^a   Camós, Mireia ^b   Sureda, Anna ^e   Maffioli, Margherita ^b   Marugán, Isabel ^a   Hernández Boluda, Juan Carlos ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e Sant Pau University Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HEMOGLOBIN; IMATINIB; XERODERMA PIGMENTOSUM GROUP C PROTEIN; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC 5; DNA EXCISION REPAIR PROTEIN ERCC-5; ENDONUCLEASE; NUCLEAR PROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR; XPC PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; EXCISION REPAIR; FEMALE; GENETIC POLYMORPHISM; GENOMIC INSTABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE; WILD TYPE; DNA REPAIR; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MYELOID LEUKEMIA; TREATMENT OUTCOME;

ADULT; AGED; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HAPLOTYPES; HEMOGLOBINS; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PIPERAZINES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954914140     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21726     Document Type: Article

References (29)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-453.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
3. Hochhaus A, Hughes T. Clinical resistance to imatinib: Mechanisms and implications. Hematol Oncol Clin North Am 2004;18:641-656.
4. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res 2006;12:7374-7379.
5. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806-4813.
6. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-4022.
7. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108:319-327.
8. Dierov J, Sanchez PV, Burke BA, et al. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia 2009;23:279-286.
9. Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008;68:6884-6888.
10. Canitrot Y, Falinski R, Louat T, et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003;102:2632-2637.
11. Fernandes MS, Reddy MM, Gonneville JR, et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009;114:1813-1819.
12. Deutsch E, Dugray A, AbdulKarim B, et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001;97:2084-2090.
13. Stoklosa T, Poplawski T, Koptyra M, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008;68:2576-2580.
14. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1:22-33.
15. de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev 1999;13:768-785.
16. Sliwinski T, Czechowska A, Szemraj J, et al. STI571 reduces NER activity in BCR/ABL-expressing cells. Mutat Res 2008;654:162-167.
17. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-1530.
18. Guillem V, Tormo M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 2008;49:204-217.
19. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
20. Sole X, Guino E, Valls J, et al. SNPStats: A web tool for the analysis of association studies. Bioinformatics 2006;22:1928-1929.
21. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-434.
22. Khan SG, Metter EJ, Tarone RE, et al. A new xeroderma pigmentosum group C poly(AT) insertion/deletion polymorphism. Carcinogenesis 2000;21:1821-1825.
23. Le Morvan V, Longy M, Bonaiti-Pellie C, et al. Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients. Int J Cancer 2006;119:1732-1735.
24. Chavanne F, Broughton BC, Pietra D, et al. Mutations in the XPC gene in families with xeroderma pigmentosum and consequences at the cell, protein, and transcript levels. Cancer Res 2000;60:1974-1982.
25. Yang ZH, Liang WB, Jia J, et al. The xeroderma pigmentosum group C gene polymorphisms and genetic susceptibility of nasopharyngeal carcinoma. Acta Oncol 2008;47:379-384.
26. Sak SC, Barrett JH, Paul AB, et al. Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:2537-2541.
27. Hansen RD, Sorensen M, Tjonneland A, et al. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res 2007;619:68-80.
28. Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002;23:295-299.
29. Zhu Y, Yang H, Chen Q, et al. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst) 2008;7:141-148.